Codexis Inc. (CDXS)
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
Codexis Q2 Earnings Call Highlights
Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)
CDXS is now shifting toward differentiated enzymes and ECO Synthesis, which I think could pay off as commoditized small molecules become less attractive. We've now seen a customer manufacturing order, as well as CDMO evaluations that validate there's interest in CDXS's offerings. However, I concede that this bull case remains inherently speculative until we see recurring commercial demand or larger contracts.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA therapeutics market, offering scalable, high-margin enzymatic manufacturing as a disruptive alternative to chemical synthesis. Operational improvements included gross margin expansion to 64%, narrowed net loss, and SG&A expense reductions, positioning CDXS for financial sustainability.
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.
Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
